

CURRICULUM VITAE  
Bob Wodecki, MD

**Research Address:** Carolina Specialty Care  
293 Old Mocksville Road  
Statesville, NC 28625  
[bwodecki@carolinasplycare.com](mailto:bwodecki@carolinasplycare.com)

**Site Affiliation:** DJL Clinical Research, PLLC  
2021-Present  
431 N Wendover Rd  
Charlotte, NC 28211

**Education:**

1991-1993 Fellowship - Rheumatology  
Long Island Jewish Medical Center  
Long Island Campus for the Albert Einstein College of Medicine  
New Hyde Park, New York

1989-1991 Residency – Internal Medicine  
St Vincent’s Medical Center  
Staten Island, New York

1988-1989 Internship  
St Vincent’s Medical Center  
Staten Island, New York

1982-1986 Medical School (MD)  
Nicolas Copernicus Medical Academy  
Cracow, Poland

1982 Major: Chemistry  
State University of Old Westbury  
Old Westbury, New York

**Honors:**

1991 Chief Medical Resident  
St Vincent’s Medical Center  
Staten Island, New York

1988 Intern of the Year Award  
St Vincent’s Medical Center  
Staten Island, New York

1981 Academic Excellence and Academic Achievement Award in Mathematics  
State University of New York College at Old Westbury  
Old Westbury, New York

CURRICULUM VITAE  
Bob Wodecki, MD

**Certification & Licensure:**

- American Board of Internal Medicine
- National Board of Physicians and Surgeons
- American Board of Rheumatology
- North Carolina Medical License

**Professional Membership:**

- American Medical Association
- American College of Rheumatology
- American Medical Association (AMA)

**Professional Experience:**

1993-Present                      Rheumatologist/CEO  
Carolina Specialty care  
Statesville, North Carolina

**Research Experience:**

**Principal Investigator** - Phase III double blind, placebo controlled, randomized comparison study for treating signs and symptoms of osteoarthritis of the knee

**Principal Investigator** – Phase III double blind, placebo-controlled, randomized comparison study for treating signs and symptoms of Rheumatoid Arthritis

**Principal Investigator** – Phase III, double blind, placebo-controlled, randomized comparison study treating signs and symptoms of Rheumatoid Arthritis, extension Study

**Principal Investigator** – Phase III, double blind, placebo-controlled, dose ranging study to stress the safety and efficiency of Nabumatone in patients with Osteoarthritis of the knee

**Principal Investigator** – Wyeth-Ayerst: Osteoarthritis of the knee, Phase III, Synvisc vs saline trial

**Primary Investigator** – Tramadol ER 300 mg QD with placebo in patients with moderate to severe chronic lower back pain, multicenter, placebo controlled

**Primary Investigator** – Multicenter, double blind, placebo controlled, randomized comparison study of the efficacy and safety of Valdecoxib 10 mg QD, Valdecoxib 20 mg QD, Valdecoxib 40 mg QD, and Naproxen 500 mg BID in Rheumatoid Arthritis


**Primary Investigator** – Radius I, Radius II; Rheumatoid Arthritis DMARD intervention and utilization study


**Co-Investigator** – Phase IIb randomized, double blind, placebo-controlled study of the effect of H5G1.1-MAB on RA patients with active disease despite receiving Methotrexate or Leflunomide

**Co-Investigator** – Assessment of the efficacy of treatment by Celecoxib 200 mg QD and 400 mg QD on the symptoms of Ankylosing Spondylitis compared to Naproxen and placebo

CURRICULUM VITAE  
Bob Wodecki, MD

My signature verifies the information in this document is accurate and updated appropriately.

  
Signature

  
Date